<DOC>
	<DOCNO>NCT02759718</DOCNO>
	<brief_summary>Chromogranin A ( CgA ) glycoprotein molecular weight 49 52 kDa produce chromaffin cell adrenal medulla , enterochromaffin-like ( ECL ) cell , endocrine cell stomach pancreas , precursor several functional peptide include vasostatin pancreastatin . Importantly , CgA measure serum plasma detect within secretory vesicle general diagnostic biomarker neuroendocrine tumor ( NETs ) , plasma CgA level also provide information regard tumor burden response treatment . It sensitivity specificity 27 % 81 % . Some study note association CgA concentration tumor location degree differentiation . It also propose plasma CgA level frequently elevate well-differentiated tumor compare poorly differentiate tumor midgut . Some clinical series provide evidence association plasma CgA level extent disease , tumor burden , presence metastasis , high baseline level CgA suggestive poor prognosis . However , exist still controversy effectiveness serum CgA level diagnostic relevance , treatment response surgical resection sandostatin analog , clinicopathologic feature pancreatic neuroendocrine tumor ( PNETs ) . To date , moreover , precise association CgA level survival clearly demonstrate , although number study suggest relationship may exist . There , especially , relevant data value serum CgA level clinical usefulness Korean population .</brief_summary>
	<brief_title>Clinical Effectiveness Serum Chromogranin A Levels Diagnostic Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description>An interventional , prospective , multi center pilot study assess clinical relevance CgA level patient PNET perform current clinical practice . There measurement CgA level baseline ( preoperative measure consent ) afterwards , 3 , 6 , 12 , 24 month resection . Immunoradiometric assay ( IRMA , normal value : &lt; 100 ng/mL ) use . The collection blood sample proceed detail : Extraction sample serum collection : 7 ml blood without anticoagulant allow sit 30 min room temperature serum separate centrifugation ( 3500 rpm ) . The serum store -20ÂºC Assessments : Baseline ( preoperative measure consent ) , 3,6 , 12 , 24 month Clinical parameter : weight , height , performance status , vital sign include blood pressure , clinical sign symptom , survival data Blood biochemical parameter : Sodium , potassium , calcium , glucose , urea , creatinina , bilirubin , alkaline phosphatase , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) . Computed tomography ( CT ) : preoperative condition , 3,6,12,24 month resection .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Endocrine Gland Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Patients differential diagnosis PNET preoperative radiologic diagnosis Life expectancy equal 6 month write informed consent participate study renal insufficiency take proton pump inhibitor cardiac insufficiency grade 3 4 chronic atrophic gastritis . multiple endocrine neoplasia Cushing 's syndrome mixed tumour pheochromocytoma medullary thyroid carcinoma . previous history malignant tumour , exception carcinoma situ uterine cervix nonmelanoma skin cancer follow study psychology geographic reason .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>pancreatic neuroendocrine tumor</keyword>
	<keyword>chromogranin A</keyword>
</DOC>